EBS Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
234.3M
+50.1%
156.1M
+5.0%
148.7M
-35.7%
231.1M
+64.0%
140.9M
Cost of Revenue
97.1M
+34.9%
72.0M
-15.2%
84.9M
-1.2%
85.9M
+28.4%
66.9M
Gross Profit
137.2M
+63.1%
84.1M
+31.8%
63.8M
-56.1%
145.2M
+96.2%
74.0M
Operating Expenses
262.3M
+256.4%
73.6M
-19.7%
91.7M
+33.5%
68.7M
-5.1%
72.4M
R&D
9.2M
-12.4%
10.5M
-13.2%
12.1M
-10.4%
13.5M
+8.0%
12.5M
SG&A
44.6M
-4.3%
46.6M
-8.8%
51.1M
+31.4%
38.9M
-11.0%
43.7M
Operating Income
-125100000
-1291.4%
10.5M
+137.6%
-27900000
-136.5%
76.5M
+4681.3%
1.6M
EBITDA
90.2M
+165.3%
34.0M
+335.9%
7.8M
-92.2%
99.9M
+298.0%
25.1M
Net Income
-180200000
-2750.0%
6.8M
+112.5%
-54600000
-206.6%
51.2M
+526.7%
-12000000
EPS (Basic)
$-3.49
-2784.6%
$0.13
+112.4%
$-1.05
-209.4%
$0.96
+536.4%
$-0.22
EPS (Diluted)
$-3.49
-5085.7%
$0.07
+107.5%
$-0.93
-202.2%
$0.91
+513.6%
$-0.22
Shares (Diluted)
51.6M
-8.7%
56.5M
-3.9%
58.8M
+4.1%
56.5M
+4.2%
54.2M
Emergent Biosolutions (EBS) โ€” Financials